九州影院

The BMCS is delighted to announce that Dr Mike Hann will be the 2024 inductee to its Hall of Fame, and the recipient of the associated medal.

Mike鈥檚 contributions to medicinal chemistry and drug discovery span multiple aspects, encompassing computational chemistry, chemoinformatics and chemical biology. He is renowned for his seminal contributions to fragment-based hit discovery as well as important contributions to automated / virtual compound library design. He is also synonymous with druggability / tractability assessment, and lipophilicity control. Mike has also made important contributions to the importance and measurement of intracellular drug concentrations. Mike is also recognized as an excellent communicator and for his role in educating future generations, being viewed as one of the key scientists that should be highlighted for future generations of researchers to know about.

Mike鈥檚 medal presentation and award lecture will take place at RSC-BMCS/SCI Targeting Protein Degradation meeting in October 2024 at Cranfield University, UK.

The BMCS is delighted to announce that Professor Andrew Hopkins, FRS FMedSci FRSC, will be the 2023 inductee to its Hall of Fame, and the recipient of the associated medal.

Andrew is widely recognized for his seminal contributions to the use of informatics in drug design. His contributions have been highly impactful as evidenced by his highly cited papers in the area of Ligand Efficiency (LE), Chemical Beauty (QED) as well as the 鈥渄ruggable genome鈥�. Andrew has been an early pioneer for the use of artificial intelligence (AI) and machine learning (ML) in drug discovery, and whilst it is a nascent field, it holds much potential for impact in the future. Combining his drug discovery expertise with his entrepreneurial spirit, Andrew founded and is leading, as Chief Executive, Exscientia plc, an AI-driven company dedicated to changing the way drugs are discovered. He led the teams that discovered the first drugs to enter human clinical trials, which were designed with the extensive use of ML and AI generative methods.

The purpose of this award is to recognize prominent chemists for outstanding, sustained, and significant scientific impact, or contributions to any area of interest to the BMCS, e.g., medicinal chemistry, agriscience, bioorganic chemistry, chemical biology.

The BMCS is delighted to announce that Dr Karin Briner will be the 2022 inductee to its Hall of Fame, and the recipient of the associated medal.

Karin is widely recognized as a leader of industrial medicinal chemists. She led Medicinal 九州影院 and Drug Discovery Teams at Lilly and then Global Discovery 九州影院 at Novartis where she had responsibility for over 600 scientists focusing on delivering clinical candidates in unprecedented target space with diverse modalities, such as low molecular weight molecules, radioligand therapies, peptides, antibody-drug conjugates, RNA-based compounds, and contributions to the discovery of umibecestat and branaplam. Very recently, she has joined Genentech as head of Drug Discovery.

Those who have worked with Karin have experienced an incredibly committed individual whose sharp analytical skills are coupled with a genuine concern for people. In all her roles Karin has been an outstanding mentor who has furthered the career of many chemists and other scientists.

The BMCS is delighted to announce that Professor Dame Carol Robinson, DBE FRS FMedSci FRSC, Dr Lee鈥檚 Professor of 九州影院 and Director of the Kavli Institute for Nanoscience Discovery at the University of Oxford, will be the 2021 inductee to its Hall of Fame and the recipient of the associated medal.

Carol Robinson is globally recognised as a leader in the development of mass spectrometry techniques to problems in chemical biology. Her ground-breaking research on the three-dimensional structure of proteins has demonstrated the power of these techniques in studying large molecular compounds. Much of her research has involved pushing the limits of electrospray mass spectrometry, demonstrating that important complexes can be generated and studied in the gas phase. Her cutting-edge work finds many applications from antibiotic resistance to drug design in both academia and industry. In addition to her academic role, she founded a successful biotechnology company which focuses on mass spectrometry to discover novel medicines.

2020

David Rees PhD

The BMCS is delighted to announce that David Rees PhD, FRSC, FMedSci, Chief Scientific Officer at Astex Pharmaceuticals, will be the 2020 inductee to its Hall of Fame, and the recipient of the associated medal.

David is recognised internationally for his innovative use of chemistry in drug discovery. His research has forged bridges between academia and industry and he has held prominent positions in learned societies such as the 九州影院. He has led collaborations resulting in the discovery of three launched drugs, the anaesthetic agent Sugammadex which has been used in over 30 million patients in 60 countries, and the anti-cancer agents Ribociclib and Erdafitinib, both predicted to achieve blockbuster status. Much of Astex鈥檚 industry-leading productivity has been dependant on David鈥檚 chemical expertise. David is well known for his calm authority, scientific rigor and enthusiasm, and has over 140 publications and patents.

The formal medal presentation was made at the 21st RSC / SCI Medicinal 九州影院 symposium on 14th September 2021.

2019

Sir Simon Campbell

The RSC-BMCS is delighted to announce that Sir Simon Campbell CBE FRS FMedSci will be the 2019 inductee to its Hall of Fame, and the recipient of the associated medal.

Sir Simon has made notable and long standing contributions to the pharmaceutical industry and to the wider chemistry community in the UK with many significant scientific achievements. At Pfizer, he was a key member of the research teams that discovered Cardura, Norvasc (Istin) and Viagra which all became 鈥渂est in class鈥� with respect to therapeutic profile and commercial success. He has co-authored over 120 publications and patents and has received various national and international awards including the RSC BMCS Lifetime Achievement Award in 2016. Sir Simon served as President of the RSC 2004-06, and was appointed CBE for Services to Science in 2006 followed by a Knighthood for Services to 九州影院 in 2015. His current scientific activities are largely focused on drug discovery for neglected diseases including malaria and TB.

2018

Professor C Robin Ganellin

The inaugural inductee to the BMCS Hall of Fame was Professor C Robin Ganellin FRS, Emeritus Professor of Medicinal 九州影院 at University College London. Professor Ganellin has inspired chemists and those in the pharmaceutical industry for decades. He devised the syllabus and taught for many years at the now well established RSC Medicinal 九州影院 Summer School. He is a drug hunter, and has had exceptional industrial and academic careers. His pioneering work, including the discoveries of the first histamine H2 and H3 receptor antagonists as medicines, has changed the lives of millions of patients.